Treatment of SB-HCC tumors with VSV-IFNß-Lcn2 VSV was still not able to enhance therapy compared to anti-PD-L1 alone, although the presence of Lcn2 did prevent the inhibition of the effects of anti-PD-L1 alone (Fig. 6). Here, LCN2 is linked to hepatocellular carcinoma.